skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 

EnWave Corporation (TSXV:ENW / FSE:E4U) has signed a material transfer agreement with MedImmune Limited, an affiliate of AstraZeneca AB (LSE:STO), to facilitate the trialing of EnWave’s Radiant Energy Vacuum technology for the dehydration of liquid monoclonal antibody formulations.

The deal has important implications for a technology that could be used for dehydrating Covid treatments and indeed even vaccines faster than more conventional methods. This has been borne out by further research from Merck (see below).

Proof of concept trials underway

Under the terms of the deal, AstraZeneca will send proprietary materials to EnWave’s testing facility in Vancouver, Canada to conduct initial proof-of-concept trials. If successful, the two companies intend to negotiate a more robust agreement to allow for further research and development activities.

This is a major development for EnWave Corporation, a Vancouver-based advanced technology company, which has developed a Radiant Energy Vacuum – an innovative, proprietary method for the precise dehydration of organic materials.

EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV technology, shortening the time from harvest to high-quality, marketable cannabis products.

Monoclonal antibody treatments have played important role

The AstraZeneca deal has major implications for EnWave. Monoclonal antibody treatments are already being used to assist Covid victims with fighting the disease. While neither party has specifically mentioned solutions for the pandemic, we note that Regeneron has been spearheading this sort of treatment in the US market. Former president Donald Trump was treated with a monoclonal antibody when he contracted Covid.

REV technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors, including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with innovative, disruptive companies in multiple verticals for the use of REV technology. It has signed over forty royalty-bearing licenses to date in twenty countries worldwide.

In addition to these licenses, EnWave established a Limited Liability Corporation, NutraDried Food Company, to manufacture, market, and sell all-natural dairy snack products in the United States, including the Moon Cheese brand.

But the excitement of investors revolves around the technology’s applicability within vaccines and other Covid treatments.

Subscribe for more stories like this, 8am weekdays - for free!

Merck evaluation of EnWave technology

Merck & Co. has recently published a research paper citing EnWave’s freezeREV process as a viable manufacturing alternative to vial-based lyophilization for vaccines and biologics. The research article entitled “Evaluation of Microwave Vacuum Drying as an Alternative to Freeze-Drying of Biologics and Vaccines: The Power of Simple Modeling to Identify a Mechanism for Faster Drying Times Achieved with Microwave” was published in the January 19, 2021 edition of PharmSciTech, the official journal of the American Association of Pharmaceutical Scientists.

Merck’s nine-month evaluation used a lab-scale freezeREV unit manufactured by EnWave specifically for the dehydration of pharmaceutical products. The goal of the study was to determine the uniformity and repeatability of Microwave Vacuum Drying (MVD) when used to dry liquid vaccines in vials. This evaluation is the first of its kind to scientifically document the efficacy of microwave-vacuum drying, more specifically freezeREV, for the drying of vaccines.

The authors of the research article note that both the global pandemic and the rapid spread of COVID-19 have emphasised the need for accelerated vaccine development and on-demand, flexible manufacturing options.

Faster alternative to freeze drying of vaccines and proteins

The published evaluation results stated that “Microwave vacuum drying serves as a faster alternative to freeze drying of biologically active materials such as vaccines, proteins, and microorganism cultures”.

Data from the study shows that EnWave’s freezeREV process reduces drying cycle times by 80% to 90% while maintaining product activity and stability when compared to lyophilization.

Lyophilization drying times are seen as a significant bottleneck for vaccine manufacturing. The research article also confirmed that EnWave’s freezeREV process demonstrates “comparability between EnWave’s freezeREV and freeze-dried samples” for drying uniformity and repeatability. The significant decrease in drying times was also accompanied by increased manufacturing flexibility.

Application within food and cannabis areas

EnWave has introduced REV as a disruptive dehydration platform in the food and cannabis sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently offers two distinct commercial REV platforms: nutraREV which is a drum-based system that dehydrates organic materials quickly and at low-cost, and, quantaREV which is a tray-based system used for continuous, high-volume low-temperature drying.


Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Stuart Fieldhouse

Stuart Fieldhouse

Stuart Fieldhouse has spent 25 years in journalism and marketing, including as a wealth management editor for the Financial Times group, covering capital markets and international private banking, and as an investment banking correspondent for Euromoney in Hong Kong. He was the founder editor of The Hedge Fund Journal.

Stuart has worked at CMC Markets, supporting the re-launch of its global financial spread betting and CFD trading platforms. He is also the author of two books on trading, published by Financial Times Pearson. Based in The Armchair Trader’s London office, Stuart continues to advise fund managers, private banks, family offices and other financial institutions.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.


Subscribe for more stories like this, 8am weekdays - for free!

Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top